about
A trial-based cost-effectiveness analysis of erlotinib alone versus platinum-based doublet chemotherapy as first-line therapy for Eastern Asian nonsquamous non-small-cell lung cancerTherapeutic options in docetaxel-refractory metastatic castration-resistant prostate cancer: a cost-effectiveness analysisWithin a smoking-cessation program, what impact does genetic information on lung cancer need to have to demonstrate cost-effectiveness?Cost-effectiveness analysis of pemetrexed versus docetaxel in the second-line treatment of non-small cell lung cancer in Spain: results for the non-squamous histology population.Survival, quality-adjusted survival, and other clinical end points in older advanced non-small-cell lung cancer patients treated with albumin-bound paclitaxel.Cost-effectiveness of a 14-gene risk score assay to target adjuvant chemotherapy in early stage non-squamous non-small cell lung cancer.Adverse events among the elderly receiving chemotherapy for advanced non-small-cell lung cancerCost-effectiveness of pazopanib in advanced soft tissue sarcoma in the United kingdom.Treatment of malignant pleural effusion: PleuRx catheter or talc pleurodesis? A cost-effectiveness analysis.Cost effectivenes of erlotinib versus chemotherapy for first-line treatment of non small cell lung cancer (NSCLC) in fit elderly patients participating in a prospective phase 2 study (GFPC 0504)(18)F-fluorodeoxyglucose positron emission tomography/computed tomography accuracy in the staging of non-small cell lung cancer: review and cost-effectivenessGene-guided gefitinib switch maintenance therapy for patients with advanced EGFR mutation-positive non-small cell lung cancer: an economic analysisCost-utility analysis of maintenance therapy with gemcitabine or erlotinib vs observation with predefined second-line treatment after cisplatin-gemcitabine induction chemotherapy for advanced NSCLC: IFCT-GFPC 0502-Eco phase III studyEconomic outcomes of maintenance gefitinib for locally advanced/metastatic non-small-cell lung cancer with unknown EGFR mutations: a semi-Markov model analysis.Cost-effectiveness of multiplexed predictive biomarker screening in non-small-cell lung cancer.Cost effectiveness of lanthanum carbonate in chronic kidney disease patients in Spain before and during dialysis.Trial-Based Cost-Utility Analysis of Icotinib versus Gefitinib as Second-Line Therapy for Advanced Non-Small Cell Lung Cancer in ChinaEpidermal Growth Factor Receptor Mutation (EGFR) Testing for Prediction of Response to EGFR-Targeting Tyrosine Kinase Inhibitor (TKI) Drugs in Patients with Advanced Non-Small-Cell Lung Cancer: An Evidence-Based AnalysisEconomic Evaluation of Companion Diagnostic Testing for EGFR Mutations and First-Line Targeted Therapy in Advanced Non-Small Cell Lung Cancer Patients in South KoreaCost-effectiveness and resource use of implementing MRI-guided NACT in ER-positive/HER2-negative breast cancers in The Netherlands.Economic Evaluations of First-Line Chemotherapy Regimens for Pancreatic Cancer: A Critical Review.Cost effectiveness of personalized therapy for first-line treatment of stage IV and recurrent incurable adenocarcinoma of the lungHealth state utility valuation in radioactive iodine-refractory differentiated thyroid cancerUtility values associated with advanced or metastatic non-small cell lung cancer: data needs for economic modeling.Estimating quality adjusted progression free survival of first-line treatments for EGFR mutation positive non small cell lung cancer patients in The NetherlandsQuality-adjusted survival following treatment of malignant pleural effusions with indwelling pleural catheters.Cost-Utility of a Prognostic Test Guiding Adjuvant Chemotherapy Decisions in Early-Stage Non-Small Cell Lung CancerUtility values for advanced soft tissue sarcoma health States from the general public in the United kingdomExploratory Cost-Effectiveness Analysis of Response-Guided Neoadjuvant Chemotherapy for Hormone Positive Breast Cancer Patients.Cost-effectiveness of pazopanib compared with sunitinib in metastatic renal cell carcinoma in CanadaTreatment of malignant pleural effusion: a cost-effectiveness analysis.Trabectedin for the treatment of advanced metastatic soft tissue sarcoma: a NICE single technology appraisal.Vemurafenib for the treatment of locally advanced or metastatic BRAF V600 mutation-positive malignant melanoma: a NICE single technology appraisal.Cost-effectiveness of therapies for melanoma.Cost-effectiveness analysis of the addition of bevacizumab to chemotherapy as induction and maintenance therapy for metastatic non-squamous non-small-cell lung cancer.A cost-effectiveness analysis of first-line induction and maintenance treatment sequences in patients with advanced nonsquamous non-small-cell lung cancer in France.Pharmacoeconomic analysis for pemetrexed as a maintenance therapy for NSCLC patients with patient assistance program in China.Economic evaluation of sequencing strategies in HER2-positive metastatic breast cancer in Mexico: a contrast between public and private payer perspectives.Cost-Effectiveness of Radiation and Chemotherapy for High-Risk Low-Grade Glioma.The Clinical and Economic Impact of Inaccurate EGFR Mutation Tests in the Treatment of Metastatic Non-Small Cell Lung Cancer.
P2860
Q28487847-795152D7-CB55-43C6-B7C6-A36A0A7521CDQ28533222-EBDAFEC1-E00C-44EF-A0B2-1366192010CAQ30496856-DEF737E0-F563-46CA-BC46-F4B6B8E10121Q30977332-DB659CBC-775B-4EC0-8296-C046473FEBB5Q33423320-1DE637A7-6CEA-4251-A762-830BE777D83BQ33577838-A6942B2A-0F18-409B-84D8-339FC6C53FBFQ33628784-263AC93E-8767-4D20-B3AB-926206136108Q33850011-DC8FFF90-4B0B-4151-8667-70A132B37302Q34129663-349F5F8C-9217-48B7-99CE-818C385207F0Q34346373-A65E1BCE-56D6-4A92-8C72-56D0986231EBQ34546800-DA35B269-1B22-4E66-8C44-928398CB9895Q34566773-3F448AAF-27EF-4FF1-91D3-45365CE922EDQ34996046-CA97D166-96FF-4827-9B3F-7B2D77F342E1Q35106391-D6764C0E-B5E2-48DB-BFC2-07900BFA02CBQ35394529-BDC631F0-1994-4823-A2A0-D3156A665102Q35743692-CBFDFEF3-D928-4C68-B4D5-6E8F1E7B2379Q35970324-F6AC1F31-04B7-45ED-BAC1-7BDA27C1F212Q36040002-F5C4518A-4069-4C0E-9F6E-16BBF1AA4FBEQ36092393-C0BBCADD-39D8-42A7-9DB0-97E46E3CAA8FQ36123151-575BC7E9-F4B0-4B8D-96F5-D200B993BF6DQ36135938-38357246-AA21-4EC3-BAB8-A3B5D4CA270EQ36226281-D76B2CC5-E868-45BA-9D4B-DCE514B5475DQ36265153-188F90B4-BDA0-4ABA-951A-A9E7A8C908C3Q36320798-3DD66F44-5D76-400D-885D-5AAE2F536AD8Q36380514-8200A0D6-4744-407F-A8EF-6F2672D3D033Q36411373-CD69B32A-FD33-4469-86AF-A955EDFE26D0Q36558386-9715A896-7F9E-4CA0-9BA2-79642715E651Q36731032-FCB76F5F-9B21-4667-AE52-8A13D0B93F09Q36848631-5CC63BDC-F14D-4C4B-8F56-EA465B45BC41Q37152908-30A217C1-F7B0-45D6-85C2-1255B1076489Q37199528-8235039C-44A0-4B3B-BA3B-8E3A0159F659Q38097338-F8EE5E86-3629-485B-B728-02BA31D3B36CQ38151578-9B847F72-E960-452D-9A4E-08796F02AA65Q38363756-F93C24BB-E89A-42CB-9F04-2B22B3B81095Q38369105-D4418149-9F4A-478A-9CD4-3A155C42F914Q38598931-235D89B2-A6D7-4BA4-BC5A-3CD19452C4B5Q38603487-039A8794-4800-488B-A5BD-8CC81A2ADEADQ38608747-59718FC5-7F64-45F0-8A4B-177460D03A8DQ38699783-E49C82B6-7517-4F66-AE6D-CAE7A31ACE14Q38705129-EFCA6C59-943F-4051-B18D-28411E987846
P2860
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Health state utilities for non small cell lung cancer.
@en
type
label
Health state utilities for non small cell lung cancer.
@en
prefLabel
Health state utilities for non small cell lung cancer.
@en
P2093
P2860
P356
P1476
Health state utilities for non small cell lung cancer.
@en
P2093
Beenish Nafees
Jessamy Watkins
Megan Stafford
Shkun Bhalla
Sonia Gavriel
P2860
P2888
P356
10.1186/1477-7525-6-84
P577
2008-10-21T00:00:00Z
P5875
P6179
1044187224